7
May
2024

Ascendia Pharmaceuticals

Exhibitor at CPHI North America 2024 stand 1412
About Us

Ascendia is a specialty CDMO that provides custom formulations and manufacturing. Our experts deliver sophisticated formulations to enhance bioavailability, solubility and stability, while reducing toxicity using GRAS (Generally Regarded As Safe) materials and four proprietary nanotechnologies – NanoSol®, EmulSol®, AmorSol® and LipidSol®. Following formulation selection and optimization, Ascendia can scale-up a development program quickly to cGMP manufacturing of clinical materials. Ascendia’s manufacturing capabilities include sterile, injectables and orally administered dosage forms.

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • US
  • 2017
    On CPHI since
  • 2
    Certificates
  • 50 - 99
    Employees
Company types
CMO/CDMO
Manufacturer/Innovator
View company profile
Contact info
Show contact info Hide contact info
Event information
CPHI North America 2024
  • 07 May 2024 - 09 May 2024
  • Pennsylvania Convention Center, Philadelphia
  • Visit us at stand 1412

Products Featured at CPHI North America 2024

  • Amorsol

    Product Amorsol

    Ascendia pharmaceuticals offers amorsol. Features: it is a technology for the production of amorphous solid dispersions. Solid dispersions are used to increase the dissolution rate, a limiting factor for the absorption of many compounds in development today. Contact us for more information.
  • cGMP clinical batches of injectable dosage forms

    Product cGMP clinical batches of injectable dosage forms

    Ascendia pharmaceuticals offers cGMP clinical batches of injectable dosage forms. Features: a dedicated, self-contained cleanroom for conducting sterile manufacturing and fill processes is maintained. Contact us for more information.
  • cGMP clinical batches of tablet and capsule dosage forms

    Product cGMP clinical batches of tablet and capsule dosage forms

    Ascendia pharmaceuticals offers cGMP clinical batches of tablet and capsule dosage forms. Features: it require capability to granulate, blend, and roller compact to make tablet batches for immediate release and modified release applications. Contact us for more information.
  • Emulsol

    Product Emulsol

    Ascendia pharmaceuticals offers emulsol. Features: it is a technology for production of oil-in-water nano-emulsions. Nano-emulsions are meta-stable, and a high level of input energy is required to produce a nano-emulsion. Contact us for more information.
  • Lyophilization

    Product Lyophilization

    Ascendia pharmaceuticals offers lyophilization. Features: it is an equipment for producing pharmaceutical formulations. Contact us for more information.

Ascendia Pharmaceuticals Resources (1)

  • Drug Formulation Development Process Notes From A CDMO

    Whitepaper Drug Formulation Development Process Notes From A CDMO

    Pharma R&D productivity has remained stagnant in the new millennium, despite record industry growth. While new technology has improved productivity in nearly every other sector, efficiency in pharmaceutical R&D is declining (or as described by MedCity News — “broken”).What obstacles are in the way of improving productivity in the pharmaceutical industry? How can we meet these challenges? At Ascendia Pharma, we’re proud to have innovative strategies in place to help our clients get their drugs from R&D to market faster.